Everist Genomics has received the U.S. Clinical Laboratory Improvement Amendment certification required for the company to launch its OncoDefender-CRC assay, a prognostic test for assessing the risk ...
Myriad Genetics (MYGN) announced that its Prolaris prostate cancer prognostic test continues to be classified by the National Comprehensive Cancer Network, NCCN, as an ‘Advanced Tool’ in the fight ...
At the San Antonio Breast Cancer Symposium, researchers presented a study on a multimodal artificial intelligence model that integrated clinical data, pathology-based imaging, and expanded molecular ...
A new study found that a DNA sequencing test for advanced prostate cancer patients can distinguish between patients with poor and favorable prognoses. Published in Nature Communications, a new study ...
Managing the invisible: Treatment approaches after pathological complete response (pCR) to neoadjuvant chemotherapy in oral cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I ...
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Telo Genomics Corp. (TELO:CA) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology ...
Telo Genomics Corp (TSE:TELO) has released an update. Telo Genomics Corp has revealed promising results for its TeloViewSMM prognostic test, which outperformed existing models in identifying high and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results